Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI FE 1 20 versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI FE 1 20 versus TAYTULLA.
BLISOVI FE 1/20 vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol, an estrogen, and desogestrel, a progestin, which inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation and altering cervical mucus and endometrial lining to reduce likelihood of fertilization and implantation.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet orally once daily for 21 days, followed by 7 days of placebo (iron-containing) tablets. Each active tablet contains 0.1 mg levonorgestrel and 20 mcg ethinyl estradiol.
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Ethinyl estradiol: ~12-14 hours; norethindrone: ~7-8 hours; both allow once-daily dosing with steady-state reached within 7-10 days.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Renal: ~50-60% as metabolites; fecal: ~40-50% via biliary elimination; less than 10% unchanged in urine.
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive